Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Goodwill (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Goodwill for 5 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill rose 3.93% to $8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.7 million, a 3.93% increase, with the full-year FY2025 number at $8.6 million, changed N/A from a year prior.
  • Goodwill was $8.7 million for Q4 2025 at Neuphoria Therapeutics, up from $8.7 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $9.2 million in Q2 2022 to a low of $8.4 million in Q4 2024.
  • A 4-year average of $8.7 million and a median of $8.7 million in 2025 define the central range for Goodwill.
  • Peak YoY movement for Goodwill: decreased 5.12% in 2023, then rose 3.93% in 2025.
  • Neuphoria Therapeutics' Goodwill stood at $9.2 million in 2022, then dropped by 5.12% to $8.7 million in 2023, then fell by 3.86% to $8.4 million in 2024, then rose by 3.93% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Goodwill are $8.7 million (Q4 2025), $8.7 million (Q3 2025), and $8.6 million (Q2 2025).